ANEB - Anebulo Pharmaceuticals Inc logo

Anebulo Pharmaceuticals Inc

ANEB

Anebulo Pharmaceuticals develops treatments for unintentional cannabis poisoning and acute cannabinoid intoxication. Its lead candidate, selonabant, targets cannabinoid binding receptors and is in phase II trials to address cannabis toxicity.

โš•๏ธ Healthcare NASDAQ Listed 2021 $ USD
$1,000 invested 5 years ago โ†’$42today

Score Overview

1 Year
Scoreโ€”
Net Growth5.96%
Net TrendGrew
Net Income Consistencyโ€”
Rev Growthโ€”
Rev TrendShrank
Revenue Consistencyโ€”
5 Years
Scoreโ€”
Net Growth73.63%
Net Trend60%
Net Income Consistencyโ€”
Rev Growthโ€”
Rev TrendNever
Revenue Consistencyโ€”
All Time
Scoreโ€”
Net Growth73.63%
Net Trend60%
Net Income Consistency
Rev Growthโ€”
Rev TrendNever
Revenue Consistency

Explore the 2021 public Archive ranking โ†’

Where Anebulo Pharmaceuticals Inc has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. ANEB does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-23
$ 0.29โ€”
1 Year2025-10-23
$ 2.72-89.34%
5 Years2021-10-22
$ 6.85-95.77%
All Time2021-05-07
$ 7.10-95.92%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 0.00-$ 7M$ 9M
2025$ 0.00-$ 8M$ 11M
2024$ 0.00-$ 8M$ 3M
2023$ 0.00-$ 11M$ 11M
2022$ 0.00-$ 6M$ 14M
IPO2021$ 0.00-$ 30M$ 19M
ANEB - Anebulo Pharmaceuticals Inc logo

Anebulo Pharmaceuticals Inc fundamental performance

Across Anebulo Pharmaceuticals Inc's full reported history, from 2021 to 2025, revenue held from $ 0.00 to $ 0.00 and net income went from -$ 30M to -$ 8M. Revenue increased in 0% of the years measured; net income in 60%.

Membership

Explore ANEB with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,112 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year ยท Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies